Is There an Effect of Glucose Lowering Treatment on Incidence and Prognosis of Tuberculosis? A Systematic Review

Diabetes and Other Diseases-Emerging Associations (JJ Nolan, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Diabetes and Other Diseases—Emerging Associations


The association between diabetes and incidence of tuberculosis is well established, and observational studies have shown poor treatment outcome in tuberculosis related to hyperglycemia. The WHO recommends screening for diabetes among all patients with tuberculosis and optimized glycemic control aiming at improving tuberculosis outcome. However, no intervention studies support this notion. Patients with tuberculosis are often vulnerable with high degree of comorbidity, and, therefore, at high risk of adverse effects of intensive glucose control. Controlled intervention studies of the effect of glucose lowering treatment on tuberculosis outcomes are clearly warranted to justify screening for- and tight control of diabetes.


Diabetes Glycemic control Tuberculosis incidence Tuberculosis outcome Glucose lowering treatment 


Compliance with Ethics Guidelines

Conflict of Interest

Marit Eika Jørgensen is employed by Steno Diabetes Center, a research hospital working in the Danish National Health Service and owned by Novo Nordisk A/S.

Daniel Faurholt-Jepsen declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Supplementary material

11892_2014_505_MOESM1_ESM.docx (73 kb)
ESM 1 (DOCX 73 kb)


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5:e152.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.••
    Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9:737–46. The study reviews the knowledge about the co-existence of diabetes and tuberculosis and potential mechanisms underlying the bidirectional association.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Dooley KE, Tang T, Golub JE, et al. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg. 2009;80:634–9.PubMedCentralPubMedGoogle Scholar
  4. 4.••
    WHO, International Union Against TB Lung Disease. Collaborative framework for care and control of tuberculosis and diabetes. 2011. Available at: (accessed 28 Dec 2011). This WHO paper provides a statement on bidirectional management of diabetes in tuberculosis patients and vice versa.
  5. 5.•
    Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343. doi: 10.1136/bmj.d6898. The meta-analysis document both health benefits and adverse risks associated with intensive glycemic control of diabetes.
  6. 6.•
    Marais BJ, Lönnroth K, Lawn SD, et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis. 2013;13:436–48. The paper focuses on synergies, and challenges of integration of tuberculosis care with management strategies for noncommunicable and communicable diseases.PubMedCrossRefGoogle Scholar
  7. 7.
    Wang JY, Lee LN, Hsueh PR. Factors changing the manifestation of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2005;9:777–83.PubMedGoogle Scholar
  8. 8.
    Wang CS, Yang CJ, Chen HC, et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect. 2008;137:203–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Restrepo BI, Fisher-Hoch SP, Crespo JG, et al. Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiol Infect. 2007;135:483–91.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Alisjahbana B, Sahiratmadja E, Nelwan EJ, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis. 2007;45:428–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Faurholt-Jepsen D, Range N, PrayGod G, et al. The role of diabetes on the clinical manifestations of pulmonary tuberculosis. Trop Med Int Health. 2012;17:877–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Tatar D, Senol G, Alptekin S, et al. Tuberculosis in diabetics: features in an endemic area. Jpn J Infect Dis. 2009;62:423–7.PubMedGoogle Scholar
  13. 13.
    Chang J-T, Dou H-Y, Yen C-L, et al. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formos Med Assoc. 2011;110:372–81.PubMedCrossRefGoogle Scholar
  14. 14.
    Faurholt-Jepsen D, Range N, Praygod G, et al. The role of diabetes co-morbidity for tuberculosis treatment outcomes: a prospective cohort study from mwanza, Tanzania. BMC Infect Dis. 2012;12:165.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Faurholt-Jepsen D, Range N, PrayGod G, et al. Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania. Trop Med Int Health. 2013;18:822–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Jimenez-Corona ME, Cruz-Hervert LP, Garcia-Garcia L, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax. 2013;68:214–20.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Magee MJ, Bloss E, Shin SS, et al. Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru. Int J Infect Dis. 2013;17:e404–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Syed Suleiman SA, Ishaq Aweis DM, Mohamed AJ, et al. Role of diabetes in the prognosis and therapeutic outcome of tuberculosis. Int J Endocrinol. 2012;2012. doi: 10.1155/2012/645362.
  19. 19.
    Fielder JF, Chaulk CP, Dalvi M, et al. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis. 2002;6:1114–7.PubMedGoogle Scholar
  20. 20.
    Franke MF, Appleton SC, Mitnick CD, et al. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis. 2013;56:770–6.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Kang YA, Kim SY, Jo K-W, et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respir Int Rev Thorac Dis. [Published Online First: May 8, 2013]. doi: 10.1159/000348374.
  22. 22.
    Kuo S-C, Chen Y-T, Li S-Y, et al. Incidence and outcome of newly-diagnosed tuberculosis in schizophrenics: a 12-year, nationwide, retrospective longitudinal study. BMC Infect Dis. 2013;13:351.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Mi F, Tan S, Liang L, et al. Diabetes mellitus and tuberculosis: pattern of tuberculosis, two-month smear conversion and treatment outcomes in Guangzhou, China. Trop Med Int Health. 2013;18:1379–85.PubMedCrossRefGoogle Scholar
  24. 24.
    Nandakumar N, Duraisamy K, Balakrishnan S, et al. Outcome of tuberculosis treatment in patients with diabetes mellitus treated in the Revised National Tuberculosis Control Programme in Malappuram District, Kerala, India. PLoS One. 2013;8:e76275. doi: 10.1371/journal.pone.0076275.
  25. 25.
    Orofino Rde L, do Brasil PEA, Trajman A, et al. Predictors of tuberculosis treatment outcomes. J Bras Pneumol Publicacao. 2012;38:88–97.CrossRefGoogle Scholar
  26. 26.
    Reed GW, Choi H, Lee SY, et al. Impact of diabetes and smoking on mortality in tuberculosis. PLoS One. 2013;8:e58044. doi: 10.1371/journal.pone.0058044.
  27. 27.
    Reis-Santos B, Locatelli R, Horta BL, et al. Socio-demographic and clinical differences in subjects with tuberculosis with and without diabetes mellitus in Brazil—a multivariate analysis. PLoS One. 2013;8:e62604. doi: 10.1371/journal.pone.0062604.
  28. 28.
    Singla R, Khan N, Al-Sharif N, et al. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int J Tuberc Lung Dis. 2006;10:74–9.PubMedGoogle Scholar
  29. 29.
    Tang S, Tan S, Yao L, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One. 2013;8:e82943. doi: 10.1371/journal.pone.0082943.
  30. 30.
    Wang CS, Yang CJ, Chen HC, et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect. 2009;137:203–10.Google Scholar
  31. 31.
    Wang J-Y, Lee L-N, Yu C-J, et al. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis. Respirology. 2009;14:1012–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Chiang C-Y, Lee J-J, Yu M-C, et al. Tuberculosis outcomes in Taipei: factors associated with treatment interruption for 2 months and death. Int J Tuberc Lung Dis. 2009;13:105–11.PubMedGoogle Scholar
  33. 33.
    Lisha PV, James PT, Ravindran C. Morbidity and mortality at five years after initiating Category I treatment among patients with new sputum smear positive pulmonary tuberculosis. Indian J Tuberc. 2012;59:83–91.PubMedGoogle Scholar
  34. 34.
    Picon PD, Bassanesi SL, Caramori MLA, et al. Risk factors for recurrence of tuberculosis. J Bras Pneumol Publicaçao. 2007;33:572–8.CrossRefGoogle Scholar
  35. 35.
    Banu Rekha VV, Balasubramanian R, Swaminathan S, et al. Sputum conversion at the end of intensive phase of Category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: an analysis of risk factors. Indian J Med Res. 2007;126:452–8.PubMedGoogle Scholar
  36. 36.
    Tam CM, Leung CC, Noertjojo K, et al. Tuberculosis in Hong Kong-patient characteristics and treatment outcome. Hong Kong Med J. 2003;9:83–90.PubMedGoogle Scholar
  37. 37.
    Uzundağ Işeri A, Dulkar G, Selçuk Sönmez O, et al. Factors that affect sputum culture conversion rate in hospitalized patients with pulmonary tuberculosis who were applied directly observation therapy and non-directly observation therapy. Tüberküloz Ve Toraks. 2010;58:44–52.PubMedGoogle Scholar
  38. 38.
    Güler M, Ünsal E, Dursun B, et al. Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis: sputum smear and culture conversion in tuberculosis. Int J Clin Pract. 2006;61:231–5.CrossRefGoogle Scholar
  39. 39.
    Oursler KK, Moore RD, Bishai WR, et al. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis. 2002;34:752–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Patel J, De Souza C, Jigjini S. Diabetes and tuberculosis. Ind J Tub. 1977;24:155–8.Google Scholar
  41. 41.
    Lecube A, Pachón G, Petriz J, et al. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. PLoS One. 2011;6:e23366.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Saxagliptin and tuberculosis. Prescrire Int. 2013;22:17.Google Scholar
  43. 43.
    Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. Accessed on 26 Feb 2014.
  44. 44.
    WHO: Treatment of Tuberculosis: Guidelines for National Programmes. 2009. Accessed 1 Mar 2010.
  45. 45.
    Maloney N, Britt RC, Rushing GD, et al. Insulin requirements in the intensive care unit in response to infection. Am Surg. 2008;74:845–8.PubMedGoogle Scholar
  46. 46.
    Ruslami R, Nijland HMJ, Adhiarta IGN, et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother. 2010;54:1068–74.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Nijland HMJ, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis. 2006;43:848–54.PubMedCrossRefGoogle Scholar
  48. 48.
    Gadkowski LB, Stout JE. Pharmacokinetics of Rifampicin. Clin Infect Dis. 2007;44:618–9.CrossRefGoogle Scholar
  49. 49.
    Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62:2169–83.PubMedCrossRefGoogle Scholar
  50. 50.
    Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330:1179–84.PubMedCrossRefGoogle Scholar
  51. 51.
    Wang Q, Ma A, Bygbjerg IC, et al. Rationale and design of a randomized controlled trial of the effect of retinol and vitamin D supplementation on treatment in active pulmonary tuberculosis patients with diabetes. BMC Infect Dis. 2013;13:104.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Kolling M, Winkley K, von Deden M. For someone who’s rich, it’s not a problem”. Insights from Tanzania on diabetes health-seeking and medical pluralism among Dar es Salaam’s urban poor. Glob Health. 2010;6:8.CrossRefGoogle Scholar
  53. 53.
    Griesdale DEG, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. Can Med Assoc J. 2009;180:821–7.CrossRefGoogle Scholar
  54. 54.
    Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359–67.PubMedCrossRefGoogle Scholar
  55. 55.
    Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449–61.PubMedCrossRefGoogle Scholar
  56. 56.
    Van den Berghe G, Mesotten D, Vanhorebeek I. Intensive insulin therapy in the intensive care unit. Can Med Assoc J. 2009;180:799–800.CrossRefGoogle Scholar
  57. 57.
    Adepoyibi T, Weigl B, Greb H, et al. New screening technologies for type 2 diabetes mellitus appropriate for use in tuberculosis patients [Review article]. Public Health Action. 2013;3:10–7.CrossRefGoogle Scholar
  58. 58.
    Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomized trial. Lancet. 2011;378:156–67.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Prato SD. Mega-trials in type 2 diabetes. From excitement to frustration? Diabetologia. 2009;52:1219–26.PubMedCrossRefGoogle Scholar
  60. 60.
    Gearhart MM, Parbhoo SK. Hyperglycemia in the critically ill patient. AACN Clin Issues. 2006;17:50–5.PubMedCrossRefGoogle Scholar
  61. 61.
    IDF. IDF diabetes atlas. 6th ed. Brussels: International Diabetes Federation; 2013.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Marit Eika Jørgensen
    • 1
  • Daniel Faurholt-Jepsen
    • 2
    • 3
  1. 1.Steno Diabetes CenterGentofteDenmark
  2. 2.Department of Nutrition, Exercise, and SportsUniversity of CopenhagenFrederiksbergDenmark
  3. 3.Department of Infectious DiseasesRigshospitaletCopenhagenDenmark

Personalised recommendations